PARIS — Around 15 vaccine candidates are being developed in the battle against tuberculosis to compensate for the poor efficacy of the Bacillus Calmette-Guérin (BCG) vaccine. Three of these candidates ...
The company announced today that it completed the first cohort in its first-in-human phase 1 SAD/MAD study of AKG-100, which is an oxazolidinone class of antibiotic for treatment of pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback